Clinical Trial Update: Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update examining P2Y12 inhibitor monotherapy in patients with atrial fibrillation undergoing Supraflex stent implantation during PCI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• P2Y12 inhibitors

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF) | Phase 4 | Status: RECRUITING